{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:36:25Z","timestamp":1777901785464,"version":"3.51.4"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Lipodystrophy syndromes have an estimated prevalence of 1.3\u20134.7 cases per million and as with other rare diseases conducting research can be challenging. The present review highlights recently published work that has provided insights into the field of non-HIV--associated lipodystrophy syndromes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Lipodystrophies are a heterogenous group of disorders, as such research is often focused on specific subtypes of the condition. The identification of children carrying <jats:italic toggle=\"yes\">LMNA<\/jats:italic> mutations has provided insights into the natural history of FPLD2, specifically that the adipose tissue phenotype predates the onset of puberty. Recent reports of PLIN1 heterozygous null variant carriers and the apparent absence of a lipodystrophy phenotype challenges our understanding of the molecular biology of perilipin 1 and its role in the pathogenesis of FPLD4. With a focus on therapeutics, studies delineating the differential responsiveness of PPAR\u03b3 mutants to endogenous and synthetic ligands has illustrated the potential for pharmacogenetics to inform therapeutic decisions in lipodystrophy related to <jats:italic toggle=\"yes\">PPARG<\/jats:italic> mutations, whereas robust human studies have provided insight into the food independent metabolic effects of leptin in lipodystrophy. Finally, rare syndromes of lipodystrophy continue to serve as an exemplar for the contribution of genetically determined adipose tissue expandability to metabolic disease in the general population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Lipodystrophy research continues to illuminate our understanding of this rare disease and the possibility that lipodystrophy syndromes and the metabolic syndrome may have shared pathophysiology.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mol.0000000000000613","type":"journal-article","created":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T03:14:26Z","timestamp":1558754066000},"page":"284-290","source":"Crossref","is-referenced-by-count":22,"title":["Recent developments in lipodystrophy"],"prefix":"10.1097","volume":"30","author":[{"given":"Audrey","family":"Melvin","sequence":"first","affiliation":[{"name":"Metabolic Research Laboratories, Wellcome Trust - MRC Institute of Metabolic Science, University of Cambridge"},{"name":"National Severe Insulin Resistance Service, Wolfson Diabetes & Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Stears","sequence":"additional","affiliation":[{"name":"National Severe Insulin Resistance Service, Wolfson Diabetes & Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B.","family":"Savage","sequence":"additional","affiliation":[{"name":"Metabolic Research Laboratories, Wellcome Trust - MRC Institute of Metabolic Science, University of Cambridge"},{"name":"National Severe Insulin Resistance Service, Wolfson Diabetes & Endocrine Clinic, Cambridge University Hospitals NHS Foundation Trust, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230917","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multisociety practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"R2-20230917","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJMra025261","article-title":"Acquired and inherited lipodystrophies","volume":"350","author":"Garg","year":"2004","journal-title":"N Engl J Med"},{"key":"R3-20230917","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1210\/er.2010-0020","article-title":"Genetic syndromes of severe insulin resistance","volume":"32","author":"Semple","year":"2011","journal-title":"Endocr Rev"},{"key":"R4-20230917","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.trsl.2016.12.007","article-title":"HIV and its relationship to insulin resistance and lipid abnormalities","volume":"183","author":"Non","year":"2017","journal-title":"Transl Res"},{"key":"R5-20230917","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","article-title":"Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet"},{"key":"R6-20230917","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/01.md.0000111061.69212.59","article-title":"Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature","volume":"83","author":"Misra","year":"2004","journal-title":"Medicine (Baltimore)"},{"key":"R7-20230917","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1210\/jc.2008-1703","article-title":"Complement abnormalities in acquired lipodystrophy revisited","volume":"94","author":"Savage","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R8-20230917","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1297\/cpe.26.99","article-title":"Partial lipodystrophy in patients who have undergone hematopoietic stem cell transplantation during childhood: an institutional cross-sectional survey","volume":"26","author":"Adachi","year":"2017","journal-title":"Clin Pediatr Endocrinol"},{"key":"R9-20230917","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.molmed.2015.04.004","article-title":"The genetics of lipid storage and human lipodystrophies","volume":"21","author":"Robbins","year":"2015","journal-title":"Trends Molec Med"},{"key":"R10-20230917","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.bbalip.2009.12.006","article-title":"Adipose tissue expandability, lipotoxicity and the metabolic syndrome\u2014an allostatic perspective","volume":"1801","author":"Virtue","year":"2010","journal-title":"Biochim Biophys Acta"},{"issue":"(1\u20132)","key":"R11-20230917","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11010-008-9998-8","article-title":"Perilipin A and the control of triacylglycerol metabolism","volume":"326","author":"Brasaemle","year":"2009","journal-title":"Mol Cell Biochem"},{"key":"R12-20230917","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1007487","article-title":"Perilipin deficiency and autosomal dominant partial lipodystrophy","volume":"364","author":"Gandotra","year":"2011","journal-title":"N Engl J Med"},{"key":"R13-20230917","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2337\/db14-0104","article-title":"Clinical and molecular characterization of a novel PLIN1 frameshift mutation identified in patients with familial partial lipodystrophy","volume":"64","author":"Kozusko","year":"2015","journal-title":"Diabetes"},{"key":"R14-20230917","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.1073\/pnas.101042998","article-title":"Perilipin ablation results in a lean mouse with aberrant adipocyte lipolysis, enhanced leptin production, and resistance to diet-induced obesity","volume":"98","author":"Tansey","year":"2001","journal-title":"Proc Natl Acad Sci"},{"key":"R15-20230917","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1210\/jc.2017-02662","article-title":"PLIN1 haploinsufficiency is not associated with lipodystrophy","volume":"103","author":"Laver","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"R16-20230917","first-page":"33","article-title":"Familial lipoatrophic diabetes with dominant transmission: a new syndrome","volume":"43","author":"Dunnigan","year":"1974","journal-title":"Q J Med"},{"key":"R17-20230917","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1210\/jc.2018-01922","article-title":"Regional body fat changes and metabolic complications in children with Dunnigan lipodystrophy-causing LMNA variants","volume":"104","author":"Patni","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R19-20230917","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/47254","article-title":"Dominant negative mutations in human PPAR\u03b3 associated with severe insulin resistance, diabetes mellitus and hypertension","volume":"402","author":"Barroso","year":"1999","journal-title":"Nature"},{"key":"R20-20230917","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-J\u00e4rvinen","year":"2004","journal-title":"N Engl J Med"},{"key":"R21-20230917","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s00125-018-4729-5","article-title":"Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"61","author":"Davies","year":"2018","journal-title":"Diabetologia"},{"key":"R22-20230917","doi-asserted-by":"crossref","first-page":"910","DOI":"10.2337\/diabetes.52.4.910","article-title":"Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-\u03b3","volume":"52","author":"Savage","year":"2003","journal-title":"Diabetes"},{"key":"R23-20230917","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1471-2350-7-3","article-title":"Peroxisomal proliferator activated receptor-\u03b3 deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3)","volume":"7","author":"Francis","year":"2006","journal-title":"BMC Med Genet"},{"key":"R24-20230917","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.2337\/db17-1236","article-title":"A pharmacogenetic approach to the treatment of patients with PPARG mutations","volume":"67","author":"Agostini","year":"2018","journal-title":"Diabetes"},{"key":"R25-20230917","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/ng.3700","article-title":"Prospective functional classification of all possible missense variants in PPARG","volume":"48","author":"Majithia","year":"2016","journal-title":"Nat Genet"},{"key":"R26-20230917","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1172\/JCI91578","article-title":"The long road to leptin","volume":"126","author":"Friedman","year":"2016","journal-title":"J Clin Invest"},{"key":"R27-20230917","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1210\/jcem.87.5.8624","article-title":"Serum adiponectin and leptin levels in patients with lipodystrophies","volume":"87","author":"Haque","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R28-20230917","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N Engl J Med"},{"key":"R29-20230917","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4158\/EP11229.OR","article-title":"Clinical effects of long-term metreleptin treatment in patients with lipodystrophy","volume":"17","author":"Chan","year":"2011","journal-title":"Endocr Pract"},{"key":"R30-20230917","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2014-4491","article-title":"Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin","volume":"100","author":"Diker-Cohen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"R32-20230917","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI0215001","article-title":"Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy","volume":"109","author":"Petersen","year":"2002","journal-title":"J Clin Invest"},{"key":"R33-20230917","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1172\/JCI95476","article-title":"Metreleptin improves insulin sensitivity independent of food intake in humans with lipodystrophy","volume":"128","author":"Brown","year":"2018","journal-title":"J Clin Invest"},{"key":"R34-20230917","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/43448","article-title":"Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy","volume":"401","author":"Shimomura","year":"1999","journal-title":"Nature"},{"key":"R35-20230917","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1172\/JCI122042","article-title":"Physiological responses to leptin levels in lipodystrophy: a model for other hypoleptinemias?","volume":"128","author":"Rosenbaum","year":"2018","journal-title":"J Clin Invest"},{"key":"R36-20230917","doi-asserted-by":"crossref","first-page":"T83","DOI":"10.1530\/JOE-14-0358","article-title":"The role of leptin in energy homeostasis in humans","volume":"223","author":"Rosenbaum","year":"2014","journal-title":"J Endocrinol"},{"key":"R37-20230917","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.cmet.2017.07.008","article-title":"Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans","volume":"26","author":"Stefan","year":"2017","journal-title":"Cell Metab"},{"key":"R38-20230917","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrendo.2014.185","article-title":"Biology of upper-body and lower-body adipose tissue\u2014link to whole-body phenotypes","volume":"11","author":"Karpe","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"R39-20230917","doi-asserted-by":"crossref","first-page":"E1870","DOI":"10.1210\/jc.2014-1526","article-title":"Adipose tissue and metabolic alterations: regional differences in fat cell size and number matter, but differently: a cross-sectional study","volume":"99","author":"Ryd\u00e9n","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R40-20230917","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng.3714","article-title":"Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance","volume":"49","author":"Lotta","year":"2017","journal-title":"Nat Genet"},{"key":"R41-20230917","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nature14132","article-title":"New genetic loci link adipose and insulin biology to body fat distribution","volume":"518","author":"Shungin","year":"2015","journal-title":"Nature"},{"key":"R42-20230917","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1001\/jama.2016.21042","article-title":"Genetic association of waist-to-hip ratio with cardiometabolic traits, type 2 diabetes, and coronary heart disease","volume":"317","author":"Emdin","year":"2017","journal-title":"JAMA"},{"key":"R43-20230917","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.2337\/db14-0319","article-title":"Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independent of obesity","volume":"63","author":"Scott","year":"2014","journal-title":"Diabetes"},{"key":"R44-20230917","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1001\/jama.2018.19329","article-title":"Association of genetic variants related to gluteofemoral vs. abdominal fat distribution with type 2 diabetes, coronary disease, and cardiovascular risk factors","volume":"320","author":"Lotta","year":"2018","journal-title":"JAMA"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00041433-201908000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T08:08:02Z","timestamp":1694938082000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00041433-201908000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0000000000000613","relation":{},"ISSN":["0957-9672","1473-6535"],"issn-type":[{"value":"0957-9672","type":"print"},{"value":"1473-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}